Current status of the development of trans-platinum antitumor drugs.

Abstract

The discovery in the 1990s of several trans-Pt complexes with in vitro and in vivo activity against tumor cells sensitive and/or resistant to cisplatin has forced the re-evaluation of the structure-activity relationships for platinum antitumor drugs. Because the determinant factors of cytotoxic activity of trans-platinum complexes do not follow the same patterns as those found for cisplatin and its analogues, the differences in cellular and biochemical pharmacology between trans-platinum antitumor complexes and cisplatin might be systematically exploited to design novel trans-platinum complexes with a clinical profile complementary to that of cisplatin and related analogues. Therefore, there may exist a novel molecular rationale for new platinum antitumor drugs development in the twenty-first century.

• Authors: J M Pérez, M A Fuertes, C Alonso, C Navarro-Ranninger
• Journal: Critical reviews in oncology/hematology (Crit Rev Oncol Hematol) Vol. 35 Issue 2 Pg. 109-20 (Aug 2000) ISSN: 1040-8428 [Print] Netherlands
• PMID: 10936468 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antineoplastic Agents
• DNA Adducts
• Organoplatinum Compounds
• DNA

Topics

• Antineoplastic Agents (chemistry, metabolism, therapeutic use)
• DNA (metabolism)
• DNA Adducts (chemistry, metabolism)
• Humans
• Organoplatinum Compounds (chemistry, metabolism, therapeutic use)
• Structure-Activity Relationship